IL218430A0 - Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations - Google Patents
Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulationsInfo
- Publication number
- IL218430A0 IL218430A0 IL218430A IL21843012A IL218430A0 IL 218430 A0 IL218430 A0 IL 218430A0 IL 218430 A IL218430 A IL 218430A IL 21843012 A IL21843012 A IL 21843012A IL 218430 A0 IL218430 A0 IL 218430A0
- Authority
- IL
- Israel
- Prior art keywords
- amino
- triazoles
- compositions
- preparing
- processes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- -1 triazole orotate Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58444809A | 2009-09-04 | 2009-09-04 | |
| PCT/US2010/002430 WO2011028288A1 (en) | 2009-09-04 | 2010-09-03 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
| US12/807,415 US8377973B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218430A0 true IL218430A0 (en) | 2012-04-30 |
Family
ID=43648255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218430A IL218430A0 (en) | 2009-09-04 | 2012-03-01 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8377973B2 (enExample) |
| EP (2) | EP2963023B1 (enExample) |
| JP (4) | JP2013503861A (enExample) |
| KR (1) | KR101597338B1 (enExample) |
| CN (2) | CN102595904B (enExample) |
| AP (1) | AP3345A (enExample) |
| AU (1) | AU2010290049B2 (enExample) |
| BR (1) | BR112012004539A2 (enExample) |
| CA (1) | CA2772075C (enExample) |
| CL (1) | CL2012000582A1 (enExample) |
| HK (1) | HK1212983A1 (enExample) |
| IL (1) | IL218430A0 (enExample) |
| MX (2) | MX2012002730A (enExample) |
| MY (1) | MY159430A (enExample) |
| NZ (2) | NZ598482A (enExample) |
| PH (1) | PH12015502088B1 (enExample) |
| RU (1) | RU2594155C2 (enExample) |
| SG (1) | SG178413A1 (enExample) |
| WO (1) | WO2011028288A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877785B2 (en) * | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
| US9089570B2 (en) * | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
| US10378059B2 (en) * | 2013-08-02 | 2019-08-13 | Tactical Therapeutics, Inc. | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
| KR102623581B1 (ko) * | 2016-07-18 | 2024-01-11 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
| CN112083109B (zh) * | 2019-07-08 | 2021-05-25 | 广东银珠医药科技有限公司 | 羧胺三唑杂质及其制备方法和检测方法 |
| US20220168276A1 (en) * | 2020-08-05 | 2022-06-02 | Tactical Therapeotics Inc. | Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate |
| CN112358451B (zh) * | 2021-01-11 | 2021-04-13 | 广东银珠医药科技有限公司 | 羧胺三唑的合成方法 |
| CN113582935A (zh) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用 |
| CN113620892B (zh) * | 2021-10-12 | 2022-02-22 | 广东银珠医药科技有限公司 | 羧胺三唑单晶、制备方法及其组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2415740C2 (de) | 1974-04-01 | 1983-12-01 | Servomed Arznei GmbH & Co Pharma KG, 8000 München | Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol |
| US4590201A (en) * | 1984-02-02 | 1986-05-20 | Merck & Co., Inc. | 5-amino or substituted amino 1,2,3-triazoles |
| US4847257A (en) * | 1987-08-20 | 1989-07-11 | Merck & Co., Inc. | 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents |
| JPH0356417A (ja) * | 1989-05-08 | 1991-03-12 | Merck & Co Inc | 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類 |
| US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
| US5359078A (en) | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| IL122782A (en) * | 1995-07-21 | 2003-03-12 | Gruppe Constantia | Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same |
| TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| WO2005116024A1 (en) * | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections |
| US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| EP2205596A1 (en) * | 2007-09-24 | 2010-07-14 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| US20150323994A1 (en) * | 2014-05-07 | 2015-11-12 | Immersion Corporation | Dynamic haptic effect modification |
| JP2017150532A (ja) * | 2016-02-23 | 2017-08-31 | Ntn株式会社 | 回転伝達装置 |
-
2010
- 2010-09-03 KR KR1020127008653A patent/KR101597338B1/ko active Active
- 2010-09-03 CA CA2772075A patent/CA2772075C/en active Active
- 2010-09-03 CN CN201080050000.2A patent/CN102595904B/zh active Active
- 2010-09-03 JP JP2012527868A patent/JP2013503861A/ja active Pending
- 2010-09-03 MY MYPI2012000629A patent/MY159430A/en unknown
- 2010-09-03 SG SG2012010294A patent/SG178413A1/en unknown
- 2010-09-03 US US12/807,415 patent/US8377973B2/en active Active
- 2010-09-03 WO PCT/US2010/002430 patent/WO2011028288A1/en not_active Ceased
- 2010-09-03 AP AP2012006187A patent/AP3345A/xx active
- 2010-09-03 MX MX2012002730A patent/MX2012002730A/es active IP Right Grant
- 2010-09-03 NZ NZ598482A patent/NZ598482A/en unknown
- 2010-09-03 CN CN201510116934.6A patent/CN104817507A/zh active Pending
- 2010-09-03 BR BR112012004539-3A patent/BR112012004539A2/pt not_active Application Discontinuation
- 2010-09-03 AU AU2010290049A patent/AU2010290049B2/en active Active
- 2010-09-03 EP EP15178128.3A patent/EP2963023B1/en active Active
- 2010-09-03 RU RU2012111454/04A patent/RU2594155C2/ru active
- 2010-09-03 EP EP10814093.0A patent/EP2473051B1/en active Active
-
2012
- 2012-03-01 IL IL218430A patent/IL218430A0/en unknown
- 2012-03-02 MX MX2014012090A patent/MX355198B/es unknown
- 2012-03-02 CL CL2012000582A patent/CL2012000582A1/es unknown
-
2013
- 2013-02-27 NZ NZ624636A patent/NZ624636A/en unknown
-
2015
- 2015-09-11 PH PH12015502088A patent/PH12015502088B1/en unknown
- 2015-11-02 JP JP2015215891A patent/JP2016026213A/ja active Pending
-
2016
- 2016-01-29 HK HK16101046.4A patent/HK1212983A1/zh unknown
-
2017
- 2017-08-03 JP JP2017150532A patent/JP2017203038A/ja active Pending
-
2020
- 2020-01-31 JP JP2020014827A patent/JP2020105178A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL218430A0 (en) | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | |
| HUS2000041I1 (hu) | Triazinonokat és vasat tartalmazó készítmények | |
| GB2453038B (en) | Formulations comprising an anti-microbial composition | |
| IL247741B (en) | Pharmaceutical preparations containing iron oxo-hydroxide, methods for their preparation and their uses | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| ZA200804654B (en) | Powder compositions for inhalation | |
| IL210226A (en) | Azul compound and pharmaceutical preparations containing them | |
| IL209054A0 (en) | Solid pharmaceutical formulations comprising bibw 2992 | |
| EP2222392A4 (en) | ULTRASONIC TREATMENT CHAMBER FOR PREPARING ANTIMICROBIAL FORMULATIONS | |
| IL213583A0 (en) | Solid compositions containing the ingredient rasagiline | |
| IL210316A (en) | History of Triazol Pharmacopoeias that contain them and their uses | |
| IL207063A (en) | Oil based concentrates, process for preparation, and preparations containing such concentrates | |
| IL206514A0 (en) | Triazole oxadiazoles derivatives, their preparation and pharmaceutical compositions containing them | |
| ZA200904029B (en) | Triazole formulation | |
| IL215139A0 (en) | Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof | |
| ZA201006717B (en) | Fungicidal compositions comprising 3'-bromine-2,3,4,6'-tetramethoxy-2'-6-dimethylbenzophenone | |
| ZA201002854B (en) | Amino 1,2,4-triazole derivatives as modulators of mglur5 | |
| IL200795A0 (en) | Prodrug compounds of (+)3-hydroxymorphinan, compositions comprising the same and use thereof | |
| IL200951A0 (en) | Aryl-sulphonamid compounds, compositions comprising the same, processes for the preparation of the same and uses thereof | |
| AU2010903214A0 (en) | Herbicidal Formulations Containing Pyraflufen-Ethyl and Triazine or 1,2,4-Triazinone Compounds | |
| PL391928A1 (pl) | Nowe pochodne 5-podstawionych 4-arylo-2, 4-dihydro-3H-1, 2, 4-triazolo-3-tionów oraz sposób ich otrzymywania | |
| GB0821381D0 (en) | Compositions for the treatment of dry eye | |
| GB0805874D0 (en) | Timian "secure payment" invention |